Celldex posts preclinical data from CDX-585 PD-1/ILT4 bispecific antibody program

seekingalpha2021-11-12

Celldex Therapeutics(NASDAQ:CLDX)announces preclinical data from CDX-585, the company’s bispecific antibody with dual targeting of ILT4 and PD-1 checkpoint pathways, developed from its bispecific ...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

PanaCota
2021-11-12
PanaCota
Ok
dandan_4896
2021-11-12
dandan_4896
Y
chaisiewling
2021-11-12
chaisiewling
Like
- dandan_4896:
  t
- chaisiewling:
  Like
Littlenoobie
2021-11-12
Littlenoobie
Ok
- US_watchlist:
  yah
PeiLing_Val
2021-11-12
PeiLing_Val
Like
- Littlenoobie:
  Ok
HawTK
2021-11-12
HawTK
Like and comment please
- PeiLing_Val:
  Ok

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/1175901532?lang=zh_CN&edition=full","thumbnail":"","is_english":true,"pubTime":"2021-11-12 20:16","share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","id":"1175901532","market":"us","top_or_hot":-1,"title":"Celldex posts preclinical data from CDX-585 PD-1/ILT4 bispecific antibody program","media":"seekingalpha","content":"<div>\n<p>Celldex Therapeutics(NASDAQ:CLDX)announces preclinical data from CDX-585, the company’s bispecific antibody with dual targeting of ILT4 and PD-1 checkpoint pathways, developed from its bispecific ...</p>\n\n<a href=\"https://seekingalpha.com/news/3769955-celldex-posts-preclinical-data-from-cdx-585-pd-1ilt4-bispecific-antibody-program\">网页链接</a>\n\n</div>\n","source":"seekingalpha","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Celldex posts preclinical data from CDX-585 PD-1/ILT4 bispecific antibody program</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCelldex posts preclinical data from CDX-585 PD-1/ILT4 bispecific antibody program\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-11-12 20:16 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/3769955-celldex-posts-preclinical-data-from-cdx-585-pd-1ilt4-bispecific-antibody-program><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Celldex Therapeutics(NASDAQ:CLDX)announces preclinical data from CDX-585, the company’s bispecific antibody with dual targeting of ILT4 and PD-1 checkpoint pathways, developed from its bispecific ...</p>\n\n<a href=\"https://seekingalpha.com/news/3769955-celldex-posts-preclinical-data-from-cdx-585-pd-1ilt4-bispecific-antibody-program\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"CLDX","symbol_name":"塞德斯医疗","start_time":0,"source_url":"https://seekingalpha.com/news/3769955-celldex-posts-preclinical-data-from-cdx-585-pd-1ilt4-bispecific-antibody-program","article_id":"1175901532","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1175901532","pubTimestamp":1636719409,"sourceInfo":{"source_id":"seekingalpha","name":"Seeking Alpha"},"weMediaInfo":null,"summary":"Celldex Therapeutics(NASDAQ:CLDX)announces preclinical data from CDX-585, the company’s bispecific a","collect":0,"end_time":0,"defaultTopTitle":"seekingalpha.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"CLDX":"塞德斯医疗"},"translate_title":"Celldex张贴CDX-585PD-1/ILT4双特异性抗体计划的临床前数据","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CLDX":0.9},"content_text":"Celldex Therapeutics(NASDAQ:CLDX)announces preclinical data from CDX-585, the company’s bispecific antibody with dual targeting of ILT4 and PD-1 checkpoint pathways, developed from its bispecific antibody platform.\nThe data showed that CDX-585 effectively combines the blockade of ILT4 and PD-1 into one molecule, with favorable biophysical and functional characteristics, the company said.\nThe data supports the initiation of development activities including manufacturing and IND-enabling studies, Celldex added.\nThe simultaneous inhibition of ILT4 and PD-1 checkpoints with CDX-585 led to myeloid and T cell activation which may potentially demonstrate clinical utility, particularly in the T cell checkpoint inhibitor refractory setting, the company said.\nCDX-585 also showed anti-tumor activity in a humanized mouse model of melanoma and had a favorable pharmacokinetic profile in pilot studies, without adverse effects of treatment noted in clinical observations or clinical chemistry.","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":null,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[{"id":879204670,"gmtCreate":1636725711338,"gmtModify":1636725711576,"author":{"id":"3581588474178431","authorId":"3581588474178431","name":"PanaCota","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":2,"crmLevelSwitch":0},"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/879204670","repostId":1175901532,"repostType":4,"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"CN"},{"id":879204841,"gmtCreate":1636725696723,"gmtModify":1636725697438,"author":{"id":"3576232257279797","authorId":"3576232257279797","name":"dandan_4896","avatar":"https://static.tigerbbs.com/d8b00e27a4dd6f248e38c3d78f21f188","vip":1,"crmLevel":2,"crmLevelSwitch":0},"htmlText":"Y","listText":"Y","text":"Y","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/879204841","repostId":1175901532,"repostType":4,"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"CN"},{"id":879204049,"gmtCreate":1636725690678,"gmtModify":1636725690761,"author":{"id":"3584578813080112","authorId":"3584578813080112","name":"chaisiewling","avatar":"https://static.tigerbbs.com/a9a4a1e448f0d39c51c24533166eb658","vip":1,"crmLevel":2,"crmLevelSwitch":0},"htmlText":"Like&nbsp;","listText":"Like&nbsp;","text":"Like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/879204049","repostId":1175901532,"repostType":4,"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":6551616,"gmtCreate":1636725702881,"gmtModify":1636725702987,"authorId":3576232257279797,"author":{"id":3576232257279797,"authorId":3576232257279797,"name":"dandan_4896","avatar":"https://static.tigerbbs.com/d8b00e27a4dd6f248e38c3d78f21f188","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":879204049,"type":1,"supId":0,"prevId":0,"content":"t","text":"t","html":"t"},{"id":6551614,"gmtCreate":1636725698949,"gmtModify":1636725699022,"authorId":3584578813080112,"author":{"id":3584578813080112,"authorId":3584578813080112,"name":"chaisiewling","avatar":"https://static.tigerbbs.com/a9a4a1e448f0d39c51c24533166eb658","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":879204049,"type":1,"supId":0,"prevId":0,"content":"Like ","text":"Like ","html":"Like "}],"langContent":"CN"},{"id":879621208,"gmtCreate":1636720116481,"gmtModify":1636720116601,"author":{"id":"4087110853440910","authorId":"4087110853440910","name":"Littlenoobie","avatar":"https://static.tigerbbs.com/02d08b3ef6fcfd7e08dcc2b8ebf67301","vip":1,"crmLevel":2,"crmLevelSwitch":0},"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/879621208","repostId":1175901532,"repostType":4,"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":6550832,"gmtCreate":1636721519936,"gmtModify":1636721520039,"authorId":3581244873474125,"author":{"id":3581244873474125,"authorId":3581244873474125,"name":"US_watchlist","avatar":"https://static.tigerbbs.com/c45e6bbe1cefb0fecde067a20b3c788f","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":879621208,"type":1,"supId":0,"prevId":0,"content":"<u>yah</u>","text":"<u>yah</u>","html":"<u>yah</u>"}],"langContent":"CN"},{"id":879629772,"gmtCreate":1636719883355,"gmtModify":1636719883487,"author":{"id":"3576835207750345","authorId":"3576835207750345","name":"PeiLing_Val","avatar":"https://static.tigerbbs.com/2b9811eea8b6682a917378f2b5138a22","vip":1,"crmLevel":2,"crmLevelSwitch":0},"htmlText":"Like&nbsp;","listText":"Like&nbsp;","text":"Like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":8,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/879629772","repostId":1175901532,"repostType":4,"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":6550620,"gmtCreate":1636720110305,"gmtModify":1636720110337,"authorId":4087110853440910,"author":{"id":4087110853440910,"authorId":4087110853440910,"name":"Littlenoobie","avatar":"https://static.tigerbbs.com/02d08b3ef6fcfd7e08dcc2b8ebf67301","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":879629772,"type":1,"supId":0,"prevId":0,"content":"Ok","text":"Ok","html":"Ok"}],"langContent":"CN"},{"id":879620646,"gmtCreate":1636719637113,"gmtModify":1636719637247,"author":{"id":"4087822741232210","authorId":"4087822741232210","name":"HawTK","avatar":"https://static.tigerbbs.com/184dd5a8890335d87b5cc27237101a65","vip":1,"crmLevel":2,"crmLevelSwitch":0},"htmlText":"Like and comment please&nbsp;","listText":"Like and comment please&nbsp;","text":"Like and comment please","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/879620646","repostId":1175901532,"repostType":4,"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":6550583,"gmtCreate":1636719888597,"gmtModify":1636719888629,"authorId":3576835207750345,"author":{"id":3576835207750345,"authorId":3576835207750345,"name":"PeiLing_Val","avatar":"https://static.tigerbbs.com/2b9811eea8b6682a917378f2b5138a22","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":879620646,"type":1,"supId":0,"prevId":0,"content":"Ok","text":"Ok","html":"Ok"}],"langContent":"CN"}],"isCommentEnd":false,"newsSizeData":{"likeSize":43,"commentSize":6,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.25.1","shortVersion":"4.25.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1175901532"}